Pain and King Start the Countdown

Pain Therapeutics (Nasdaq: PTIE  ) and marketing partner King Pharmaceuticals (NYSE: KG  ) have now started the clock on perhaps the most precarious period yet for their lead drug candidate, Remoxy.

Pain and King announced yesterday that they had submitted a marketing application to the FDA for the abuse-deterrent oxycodone pain drug, starting the countdown toward the agency's review.

Assuming the FDA accepts the filing as a 505(b)2 -- a change to an existing drug -- an even more important clock also starts. Rival drugmaker Purdue Pharma, maker of the similar OxyContin, can attempt to stall the Remoxy FDA with a patent challenge any time within the next 45 days.

Pain and King have always vigorously proclaimed that Remoxy does not infringe upon Purdue's OxyContin patents -- called a paragraph IV certification -- but that doesn't necessarily preclude Purdue from (rightfully or wrongfully) suing them.

If Purdue does file a lawsuit, the FDA won't approve Pain and King's Remoxy marketing application until 30 months after the lawsuit is filed or the patent challenge litigation is concluded, whichever occurs first. (Investors wanting to hedge against this near-term patent challenge risk can always use put options.)

Whatever happens with the Remoxy patent situation, most of the abuse-deterrent drugmakers received good news last month, after an advisory panel meeting sounded a relatively favorable note about this emerging class of drugs.

Purdue Pharma is in the lead; it will be the first drugmaker to get an approval decision on its own abuse-deterrent version of OxyContin. If Purdue fails to gain FDA approval at its marketing application review later this year, Pain and King will be back in the drivers seat (assuming no patent challenges), now that Alpharma (NYSE: ALO  ) also had to delay its own abuse-deterrent opioid marketing application.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a 30-day free trial subscription.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has an A+ disclosure policy.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 15, 2008, at 12:10 AM, johndough110 wrote:

    King's bet on Acura Pharmaceuticals is one you should be writing about.

    Acura has a corner on the immediate release market, while Pain/Purdue target the extended release segment.

    Acura has a patented platform with now two drug candidates and the global potential to be applied to ALL KINDS of drugs, both prescription and over the counter.

    Check it out. If not you'll hear about it soon anyhow, wishing you knew earlier.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 662731, ~/Articles/ArticleHandler.aspx, 11/23/2014 2:05:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement